Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 8/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260824 | 0.82 | CRBN (0.53) | TDP2PNMTADRA2ACRBNCA12 | |
| SCHEMBL260991 | 0.76 | CA9 (0.39) | TDP2CA12CA1CA2CA9 | |
| SCHEMBL379349 | 0.75 | TDP2 (0.48) | TDP2PNMTADRA2ACRBNCA12 | |
| SCHEMBL261144 | 0.74 | CALCRL (0.39) | ADRA2ACA12CA9TDP1JAK1 | |
| SCHEMBL10128526 | 0.74 | CRBN (0.47) | TDP2PNMTADRA2ACRBNCA12 | |
| SCHEMBL26087941 | 0.74 | CRBN (0.47) | TDP2PNMTADRA2ACRBNCAPN9 | |
| SCHEMBL19718097 | 0.72 | KDM4E (0.43) | TDP2CA12CA1CA2CA9 | |
| SCHEMBL19718094 | 0.72 | KDM4E (0.43) | TDP2CA12CA1CA2CA9 | |
| SCHEMBL12362409 | 0.72 | CALCRL (0.45) | JAK2JAK1TYK2 | |
| SCHEMBL19718109 | 0.72 | KDM4E (0.43) | TDP2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4126824-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | Theravance Biopharma R&D IP, LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1791843-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1793827-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1791843-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007061677-A2 | SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061692-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061696-A2 | SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006031491-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006031610-A2 | BICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006031513-A2 | ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006029153-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | TDP2 274/4885PNMT 3276/4885ADRA2A 3016/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | TDP2 274/4885PNMT 3276/4885ADRA2A 3016/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | TDP2 274/4885PNMT 3276/4885ADRA2A 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.